Manager TitleAgeSince
Corporate Secretary 60 08/08/2019
Director TitleAgeSince
Director/Board Member 49 21/04/2020
Director/Board Member 60 07/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-1.46%+33.37%+75.23% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
-0.82%-2.44%-17.74%+363.89% 26.38B
-0.28%+4.70%+2.10%-2.71% 25.34B
+0.57%+3.98%+25.97%-8.81% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.55%+0.01%+42.64%+160.12% 14.41B
Average -0.52%+3.20%+36.82%+174.71% 31.12B
Weighted average by Cap. -0.65%+3.08%+36.11%+135.32%
Logo Nightstar Therapeutics PLC
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company's lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company's third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.
Employees
-